Controlled trial of penfluridol and thiothixene in the maintenance treatment of chronic schizophrenic syndromes.
In a controlled trial of penfluridol and thiothixene as maintenance drugs in patients with chronic schizophrenic syndromes, some improvement over previous neuroleptics was seen with both drugs. This improvement was mainly evident in variables concerned with participation in social activities as assessed with the S-scale and by ward behaviour. The drug dosages necessary were very low and gave few and easily manageable side-effects. There was no significant difference between penfluridol and thiothixene. Penfluridol has the clear practical advantage of being the only long-acting drug for oral administration so far available.
D000293:Adolescent; D000328:Adult; D000368:Aged; D001712:Biperiden / Q000627:therapeutic use; D002746:Chlorpromazine / Q000627:therapeutic use; D002908:Chronic Disease; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010395:Penfluridol / Q000008:administration & dosage / Q000627:therapeutic use*; D010880:Piperidines / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*; D013888:Thiothixene / Q000008:administration & dosage / Q000627:therapeutic use*
D006993:Hypnotics and Sedatives; D010880:Piperidines; D001712:Biperiden; D010395:Penfluridol; D013888:Thiothixene; D002746:Chlorpromazine